CaV3.1 channels
Channel name | Cav3.1 |
Description | Voltage-gated calcium channel α1 subunit |
Other names | T-type, α13.1, α1G |
Molecular information | Human: 2377aa, O43497, NM_018896, chr. 17q22, CACNA1G1 |
Rat: 2254aa, O54898, AF027984 | |
Mouse: 2288aa, CAI25956, NM_009783 (see “Comments”) | |
Associated subunits | No biochemical evidence, small changes induced by α2δ12 and α2δ23,4 |
Functional assays | Voltage-clamp, calcium imaging |
Current | ICa,T |
Conductance | 7.5pS1 |
Ion selectivity | Sr2+ > Ba2+ = Ca2+ |
Activation | Va = —46 mV, τa = 1 ms at —10 mV5,6 |
Inactivation | Vh = —73 mV, τh = 11 ms at —10 mV5,6 |
Activators | Not established |
Gating modifiers | Kurtoxin, IC50 = 15 nM7 |
Blockers | No subtype-specific blocker8; selective for Cav3.x relative to Cav1.x and Cav2.x: mibefradil,9,10 U92032,11 penfluridol and pimozide12; nonselective: nickel (IC50 = 250 μM),13 amiloride14 |
Radioligands | None |
Channel distribution | Brain, especially soma and dendrites of neurons in olfactory bulb, amygdala, cerebral cortex, hippocampus, thalamus, hypothalamus, cerebellum, brain stem (human RNA blots,1,5 rat in situ hybridization15 and immunocytochemistry16); ovary, placenta, heart (especially sinoatrial node; mouse in situ hybridization17) |
Physiological functions | Thalamic oscillations18 |
Mutations and pathophysiology | Not established |
Pharmacological significance | May mediate effect of absence antiepileptic drugs such as ethosuximide19 and other thalamocortical dysrhythmias20 |
Comments | Splice variants that differ in their voltage dependence have been cloned5 |
aa, amino acids; chr., chromosome; U92032, 7-[[4-bis(fluorophenyl)methyl]-1-piperazinyl]methyl-2-[(2-hydroxyethyl)a mino]4-(1-methylethyl)-2,4,6-cycloheptatrien-1-one.
↵1. Perez-Reyes E, Cribbs LL, Daud A, Lacerda AE, Barclay J, Williamson MP, Fox M, Rees M, and Lee J-H (1998) Molecular characterization of a neuronal low voltage-activated T-type calcium channel. Nature (Lond) 391:896-900
↵2. Dolphin AC, Wyatt CN, Richards J, Beattie RE, Craig P, Lee J-H, Cribbs LL, Volsen SG, and Perez-Reyes E (1999) The effect of α2δ and other accessory subunits on expression and properties of the calcium channel α1G. J Physiol (Lond) 519.1:35-45
↵3. Gao B, Sekido Y, Maximov A, Saad M, Forgacs E, Latif F, Lerman M, Lee J-H, Perez-Reyes E, Bezprozvanny I, et al. (2000) Functional properties of a new voltage-dependent calcium channel α2δ auxiliary subunit gene (CACNA2D2). J Biol Chem 275:12237-12242
↵4. Hobom M, Dai S, Marais E, Lacinova L, Hofmann F and Klugbauer N (2000) Neuronal distribution and functional characterization of the calcium channel α2δ2 subunit. Eur J Neurosci 12:1217-1226
↵5. Monteil A, Chemin J, Bourinet E, Mennessier G, Lory P, and Nargeot J (2000) Molecular and functional properties of the human α1G subunit that forms T-type calcium channels. J Biol Chem 275:6090-6100
↵6. Klöckner U, Lee JH, Cribbs LL, Daud A, Hescheler J, Pereverzev A, Perez-Reyes E, and Schneider T (1999) Comparison of the Ca2+ currents induced by expression of three cloned α1 subunits, α1G, α1H and α1I, of low-voltage-activated T-type Ca2+ channels. Eur J Neurosci 11:4171-4178
↵7. Chuang RS, Jaffe H, Cribbs L, Perez-Reyes E, and Swartz KJ (1998) Inhibition of T-type voltage-gated calcium channels by a new scorpion toxin. Nat Neurosci 1:668-674
↵8. Heady TN, Gomora JC, Macdonald TL, and Perez-Reyes E (2001) Molecular pharmacology of T-type Ca2+ channels. Jpn J Pharmacol 85:339-350
↵9. Perchenet L, Bénardeau A, and Ertel EA (2000) Pharmacological properties of Cav3.2, a low voltage-activated Ca2 + channel cloned from human heart. Naunyn Schmiedeberg's Arch Pharmacol 361:590-599
↵10. Martin RL, Lee JH, Cribbs LL, Perez-Reyes E, and Hanck DA (2000) Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther 295:302-308
↵11. Avery RB and Johnston D (1997) Ca2+ channel antagonist U-92032 inhibits both T-type Ca2+ channels and Na+ channels in hippocampal CA1 pyramidal neurons. J Neurophysiol 77:1023-1028
↵12. Santi CM, Cayabyab FS, Sutton KG, McRory JE, Mezeyova J, Hamming KS, Parker D, Stea A, and Snutch TP (2002) Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci 22:396-403
↵13. Lee JH, Gomora JC, Cribbs LL, and Perez-Reyes E (1999) Nickel block of three cloned T-type calcium channels: low concentrations selectively block α1H. Biophys J 77:3034-3042
↵14. Lacinova L, Klugbauer N, and Hofmann F (2000) Regulation of the calcium channel α1G subunit by divalent cations and organic blockers. Neuropharmacology 39:1254-1266
↵15. Talley EM, Cribbs LL, Lee JH, Daud A, Perez-Reyes E, and Bayliss DA (1999) Differential distribution of three members of a gene family encoding low voltage-activated (T-type) calcium channels. J Neurosci 19:1895-1911
↵16. Craig PJ, Beattie RE, Folly EA, Banerjee MD, Reeves MB, Priestley JV, Carney SL, Sher E, Perez-Reyes E, and Volsen SG (1999) Distribution of the voltage-dependent calcium channel α1G subunit mRNA and protein throughout the mature rat brain. Eur J Neurosci 11:2949-2964
↵17. Bohn G, Moosmang S, Conrad H, Ludwig A, Hofmann F, and Klugbauer N (2000) Expression of T- and L-type calcium channel mRNA in murine sinoatrial node. FEBS Lett 481:73-76
↵18. Perez-Reyes E (2003) Molecular physiology of low-voltage-activated T-type calcium channels. Physiol Rev 83:117-161
↵19. Gomora JC, Daud AN, Weiergräber M, and Perez-Reyes E (2001) Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol 60:1121-1132
↵20. Llinás RR, Ribary U, Jeanmonod D, Kronberg E, and Mitra PP (1999) Thalamocortical dysrhythmia: a neurological and neuropsychiatric syndrome characterized by magnetoencephalography. Proc Natl Acad Sci USA 96:15222-15227